The TPM® delivery systems have been shown to be suitable for delivering both small and large molecules up to 30,000 Daltons in size.  Examples of the later successfully delivered to date include insulin (lispro and the hexamer).

TPM® delivery systems include:

-  Vesicular system -  a multi-lamellar malleable vesicular carrier whose size can be tightly controlled.  This allows TPM® to be formulated in a range of sizes, from nanometres to microns in diameter

-  Micro-emulsions - ointments and gels

-  Liquid - oral solutions

-  Patch systems - reservoir and think film matrix systems

TPM® transdermal delivery systems are:

-  Easy to formulate

-  Non-invasive

-  User-friendly

-  Anti-inflammatory and non-irritant

Additionally, the unique technology allows for the size of the vesicles to be controlled, the rate of diffusion through the skin (and as a result the systemic release rate) can also be controlled.


Phosphagenics Pain Portfolio

In the last 5 years since 2008-09 Phosphagenics has developed a range of pain products that incorporate its unique TPM® technology.  These products include opioids, NSAIDS and anaesthetics.


Phosphagenics has developed oxymorphone and oxycodone patches as their lead products for pain treatment, with an oxymorphone patch in development for the treatment of mild to severe chronic pain via systemic delivery into the bloodstream and oxycodone being developed to treat local and peripheral pain.

The target market for the TPM®/Oxymorphone patch is the total extended release market of around $6 billion pa.  The TPM®/Oxycodone patch target market is also very large being around $5-6 billion.

® technology could be applied to other opioids and it is likely that different opioid patches will be added to the portfolio in the future.